Monthly Archives: March 2013

  we really don’t need drugs…

Posted in Uncategorized | Leave a comment

A Noteworthy Discrepancy

An interesting observation made by Jill Fisher in her article Ready-to-Recruit or Ready to Consent is the attempted shift in marketing bracket made by the CRO’s. The author notes that currently the Phase I of clinical testing tends to be … Continue reading

Posted in Uncategorized | Leave a comment

Comment on “Ready-to-Recruit” or “Ready-to-Consent” Populations?

A good introductory piece by Jill Fisher, and too much to comment on in 250 words. I’ve decided to focus on the significance of recruitment times and the state of accrual. In the clinical trial context, meeting accrual targets is … Continue reading

Posted in Uncategorized | Leave a comment

Drug money

As we continue with our theme of clinical trials, Jill Fisher examines the recruitment practices for drug testing on human subjects. She does this through analyzing advertisements as well as three cases of why individuals choose to participate in these … Continue reading

Posted in Uncategorized | Leave a comment

Who Should Participate in Clinical Trials?

https://docs.google.com/file/d/0B-CzY4x3aATQYkppaXI5X0FBTlU/edit?usp=sharing Pharma champions the image of the clinical trial participant as a sufferer of a medical condition unresponsive to current market drugs, for whom participation in phase II/III trials presents an opportunity for newer, better treatment. This, however, is not … Continue reading

Video | Posted on by | Leave a comment

Jill Fisher- ‘Ready-to-Recruit’ or ‘Ready-to-Consent’

Jill Fisher examines the recruitment methods of Contract Research Organizations (CRO’s) in her article “Ready-to-Recruit’ or ‘Ready-to-Consent’ Populations Informed Consent and the Limits of Subject Autonomy”.  She claims that these organizations take advantage of populations who consent to clinical trials … Continue reading

Posted in Uncategorized | Leave a comment

Summary of Readings

The Experimental machinery of Global Clinical Trials: Case Studies From India Rajan introduces the idea that clinical trials are the experimental machinery of biocapital. Biocapital encapsulates scientific production, value generation and commodity circulation as it pertains to the biomedical field. … Continue reading

Quote | Posted on by | Leave a comment